Unique noncoding variants upstream of PRDM13 are associated with a spectrum of developmental retinal dystrophies including progressive bifocal chorioretinal atrophy.
5' Untranslated Regions
Adult
Computational Biology
/ methods
Corneal Dystrophies, Hereditary
/ diagnosis
Female
Genetic Association Studies
/ methods
Genetic Loci
Genetic Predisposition to Disease
Haplotypes
Histone-Lysine N-Methyltransferase
/ genetics
Humans
Multigene Family
Pedigree
Retinal Dystrophies
/ diagnosis
Transcription Factors
/ genetics
Whole Genome Sequencing
NCMD
PBCRA
PRDM13
macular development
macular dystrophy
whole genome sequencing
Journal
Human mutation
ISSN: 1098-1004
Titre abrégé: Hum Mutat
Pays: United States
ID NLM: 9215429
Informations de publication
Date de publication:
05 2019
05 2019
Historique:
received:
12
11
2018
revised:
23
01
2019
accepted:
24
01
2019
pubmed:
3
2
2019
medline:
10
3
2020
entrez:
3
2
2019
Statut:
ppublish
Résumé
The autosomal dominant progressive bifocal chorioretinal atrophy (PBCRA) disease locus has been mapped to chromosome 6q14-16.2 that overlaps the North Carolina macular dystrophy (NCMD) locus MCDR1. NCMD is a nonprogressive developmental macular dystrophy, in which variants upstream of PRDM13 have been implicated. Whole genome sequencing was performed to interrogate structural variants (SVs) and single nucleotide variants (SNVs) in eight individuals, six affected individuals from two families with PBCRA, and two individuals from an additional family with a related developmental macular dystrophy. A SNV (chr6:100,046,804T>C), located 7.8 kb upstream of the PRDM13 gene, was shared by all PBCRA-affected individuals in the disease locus. Haplotype analysis suggested that the variant arose independently in the two families. The two affected individuals from Family 3 were screened for rare variants in the PBCRA and NCMD loci. This revealed a de novo variant in the proband, 21 bp from the first SNV (chr6:100,046,783A>C). This study expands the noncoding variant spectrum upstream of PRDM13 and suggests altered spatio-temporal expression of PRDM13 as a candidate disease mechanism in the phenotypically distinct but related conditions, NCMD and PBCRA.
Substances chimiques
5' Untranslated Regions
0
Transcription Factors
0
PRDM13 protein, human
EC 2.1.1.-
Histone-Lysine N-Methyltransferase
EC 2.1.1.43
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
578-587Subventions
Organisme : Fight for Sight PhD studentship
ID : 1568/1569
Pays : International
Organisme : Fight for Sight Early Career Investigator Award
ID : 5045/5046
Pays : International
Informations de copyright
© 2019 Wiley Periodicals, Inc.